Contents
II Information
INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES
European Commission
2021/C 29/01 Non-opposition to a notified concentration (Case M.10066 — Carlyle/Flender) (1)
. . . 1
IV Notices
NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES
European Commission
2021/C 29/02 Euro exchange rates — 25 January 2021. . . 2
NOTICES FROM MEMBER STATES
2021/C 29/03 Winding-up proceedings – Winding-up proceedings in respect of Nederlandsche Algemene Maatschappij
van Levensverzekering ‘Conservatrix’ N.V. (the ‘Company’) (Publication made in accordance with Article 280 of Directive 2009/138/EC of the European Parliament and of the Council on the taking up and pursuit of the business of Insurance and Reinsurance (Solvency II)). . . 3
V Announcements
PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY
European Commission
2021/C 29/04 Prior notification of a concentration (Case M.10004 - EQT/Zentricity/Cajelo/Recipharm) – Candidate
case for simplified procedure (1). . . 4
2021/C 29/05 Prior notification of a concentration (Case M.10049 — Partners Group/Atlantia/Telepass) – Candidate
case for simplified procedure (1). . . 6
EN
C 29
Official Journal
of the European Union
Volume 64
Information and Notices
26 January 2021English edition
II
(Information)
INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES
AND AGENCIES
EUROPEAN COMMISSION
Non-opposition to a notified concentration (Case M.10066 — Carlyle/Flender)
(Text with EEA relevance)
(2021/C 29/01)
On 19 January 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible
with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text
of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:
— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,
— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10066. EUR-Lex is the online access to European law.
(1) OJ L 24, 29.1.2004, p. 1.
EN Official Journal of the European Union
IV
(Notices)
NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND
AGENCIES
EUROPEAN COMMISSION
Euro exchange rates (1) 25 January 2021
(2021/C 29/02)
1 euro =
Currency Exchange rate
USD US dollar 1,2152
JPY Japanese yen 126,06
DKK Danish krone 7,4406
GBP Pound sterling 0,88800
SEK Swedish krona 10,0625
CHF Swiss franc 1,0772
ISK Iceland króna 157,00
NOK Norwegian krone 10,3478
BGN Bulgarian lev 1,9558
CZK Czech koruna 26,080
HUF Hungarian forint 357,33
PLN Polish zloty 4,5409
RON Romanian leu 4,8744
TRY Turkish lira 8,9865
AUD Australian dollar 1,5728
Currency Exchange rate
CAD Canadian dollar 1,5459
HKD Hong Kong dollar 9,4199
NZD New Zealand dollar 1,6854
SGD Singapore dollar 1,6124
KRW South Korean won 1 340,18
ZAR South African rand 18,4930
CNY Chinese yuan renminbi 7,8712
HRK Croatian kuna 7,5665
IDR Indonesian rupiah 17 108,31
MYR Malaysian ringgit 4,9149
PHP Philippine peso 58,427
RUB Russian rouble 91,6732
THB Thai baht 36,438
BRL Brazilian real 6,6434
MXN Mexican peso 24,2927
INR Indian rupee 88,6300
NOTICES FROM MEMBER STATES
Winding-up proceedingsWinding-up proceedings in respect of Nederlandsche Algemene Maatschappij van Levensverzekering ‘Conservatrix’ N.V. (the ‘Company’)
(Publication made in accordance with Article 280 of Directive 2009/138/EC of the European Parliament and of the Council on the taking up and pursuit of the business of Insurance and Reinsurance (Solvency II))
(2021/C 29/03)
Insurance undertaking Nederlandsche Algemene Maatschappij van Levensverzekering ‘Conservatrix’ N.V.
Date, entry into force and nature of decision 8 December 2020
Competent authorities Court of Amsterdam, delegated judges mr. M. de Vries and mr. A.E. de Vos
Supervisory authority Court of Amsterdam, delegated judges mr. M. de Vries and mr. A.E. de Vos
Trustees appointed mr. drs. W.J.M. van Andel and mr. E.L. Zetteler
Applicable law Dutch Law
EN Official Journal of the European Union
V
(Announcements)
PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION
POLICY
EUROPEAN COMMISSION
Prior notification of a concentration (Case M.10004 - EQT/Zentricity/Cajelo/Recipharm)
Candidate case for simplified procedure
(Text with EEA relevance)
(2021/C 29/04)
1. On 18 January 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of
Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:
— EQT IX Collect EUR SCSp and EQT IX Collect USD SCSp (together ‘EQT IX’), part of the EQT group of private equity funds (‘EQT’, Luxembourg);
— Zentricity Holding AB (‘Zentricity’, Sweden); — Cajelo Invest Ltd (‘Cajelo’, Cyprus); and — Recipharm AB (‘Recipharm’, Sweden).
EQT, Zentricity and Cajelo acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Recipharm.
The concentration is accomplished by way of public bid announced on 14 December 2020.
2. The business activities of the undertakings concerned are:
— for EQT: private equity funds that invest in companies across the world, which amongst others control EQT IX, an investment fund investing primarily in Europe, with a focus on Northern Europe;
— for Zentricity: investment company focusing on investing in pharmaceutical companies primarily in Sweden, which is controlled by private individual Thomas Eldered, who also controls the pharmaceutical companies Empros Pharma AB, Flerie Creations Ltd. and Flerie Invest AB;
— for Cajelo: investment company which is controlled by private individual Lars Backsell, who also controls Glims Marketing Ltd. and Rohirrim AB, a horse breeding company.
— for Recipharm: contract development and manufacturing organization, providing drug development and manufacturing services globally to the pharmaceutical industry (e.g. for finished dose pharmaceuticals, active pharmaceutical ingredients and clinical trial materials for customers in the pharmaceutical industry), as well as packaging services and logistics services.
3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council
Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out
in the Notice.
4. The Commission invites interested third parties to submit their possible observations on the proposed operation to
the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10004 – EQT/Zentricity/Cajelo/Recipharm
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301 Postal address: European Commission
Directorate-General for Competition Merger Registry
1049 Bruxelles/Brussel BELGIQUE/BELGIË
(2) OJ C 366, 14.12.2013, p. 5.
EN Official Journal of the European Union
Prior notification of a concentration (Case M.10049 — Partners Group/Atlantia/Telepass)
Candidate case for simplified procedure
(Text with EEA relevance)
(2021/C 29/05)
1. On 18 January 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of
Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:
— Partners Group AG (together with its affiliates, ‘Partners Group’, Switzerland), — Atlantia SpA (‘Atlantia’, Italy),
— Telepass SpA (‘Telepass’, Italy), currently solely controlled by Atlantia (Italy)
Partners Group and Atlantia acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Telepass.
The concentration is accomplished by way of purchase of shares.
2. The business activities of the undertakings concerned are:
— for Partners Group: global private investment management company active in the areas of private equity, private real estate, private infrastructure and private debt;
— for Atlantia: holding company active mainly in the toll motorway and airport infrastructure sectors in Italy, Spain, France and, to a limited extent, Poland;
— for Telepass: active mainly in the provision of electronic tolling services in Europe and, in particular, in Italy.
3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the
Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council
Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out
in the Notice.
4. The Commission invites interested third parties to submit their possible observations on the proposed operation to
the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10049 — Partners Group/Atlantia/Telepass
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301 Postal address: European Commission
Directorate-General for Competition Merger Registry
1049 Bruxelles/Brussel BELGIQUE/BELGIË
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
